Phase II: Adaptive De-escalation of Radiation Therapy Dose In Favorable Risk HPV-Positive Oropharyngeal Carcinoma (ART)

Go Back to All Clinical Trials

Phase II: Adaptive De-escalation of Radiation Therapy Dose In Favorable Risk HPV-Positive Oropharyngeal Carcinoma (ART)

Brief description of study

The main goal of this study is to determine if deescalating chemoradiation treatment based on early tumor shrinkage at mid-treatment can result in similar cancer cure rates as standard treatment but fewer side effects and better quality of life.

Clinical Study Identifier: s17-00330

ClinicalTrials.gov Identifier: NCT03215719

Principal Investigator: Kenneth S Hu.

Other Investigators: Elcin Zan, Joshua K Sabari, Zujun Li, Ann M Riccobene, Gene H Kim, Tuyet-Phuong N Tran, Catherine M Concert, Moses M Tam, Babak Givi, Michael E. Pacold, Mark S Persky, Janet H. Van Cleave, Jacqueline Mojica, Milan R Amin, Paulina Galavis, Elise M Zahriah, Adam S Jacobson, Elaine Shum, Mark D Delacure.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies